- Home
- INBS vs MYNZ Comparison
INBS vs MYNZ Comparison
Compare INBS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBS
- MYNZ
- Stock Information
- Founded
- INBS 2016
- MYNZ 2021
- Country
- INBS United States
- MYNZ Germany
- Employees
- INBS N/A
- MYNZ N/A
- Industry
- INBS Medical Specialities
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- INBS Health Care
- MYNZ Health Care
- Exchange
- INBS Nasdaq
- MYNZ Nasdaq
- Market Cap
- INBS 8.7M
- MYNZ 7.0M
- IPO Year
- INBS N/A
- MYNZ 2021
- Fundamental
- Price
- INBS $1.24
- MYNZ $2.27
- Analyst Decision
- INBS
- MYNZ Buy
- Analyst Count
- INBS 0
- MYNZ 2
- Target Price
- INBS N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- INBS 113.6K
- MYNZ 303.1K
- Earning Date
- INBS 05-13-2025
- MYNZ 05-27-2025
- Dividend Yield
- INBS N/A
- MYNZ N/A
- EPS Growth
- INBS N/A
- MYNZ N/A
- EPS
- INBS N/A
- MYNZ N/A
- Revenue
- INBS $2,936,472.00
- MYNZ $893,991.00
- Revenue This Year
- INBS $280.88
- MYNZ $42.95
- Revenue Next Year
- INBS $126.26
- MYNZ N/A
- P/E Ratio
- INBS N/A
- MYNZ N/A
- Revenue Growth
- INBS 3.87
- MYNZ N/A
- 52 Week Low
- INBS $1.00
- MYNZ $0.18
- 52 Week High
- INBS $3.04
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- INBS 43.94
- MYNZ 31.65
- Support Level
- INBS $1.16
- MYNZ $2.30
- Resistance Level
- INBS $1.43
- MYNZ $2.57
- Average True Range (ATR)
- INBS 0.10
- MYNZ 0.36
- MACD
- INBS 0.02
- MYNZ -0.03
- Stochastic Oscillator
- INBS 42.42
- MYNZ 4.00
About INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.